UPLAT, a herbal treatment for reduced platelet count after chemotherapy

An open-labeled, randomized, comparative, multi centric, clinical study to evaluate the efficacy and safety of UPLAT® in Patients with all solid tumors suffering from chemotherapy induced thrombocytopenia (CIT)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036685

Enrollment

Registered

2021-09-21

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D695- Secondary thrombocytopenia

Interventions

Intervention1: UPLAT: UPLAT® is a FSSAI approved dietary supplement and its veg capsules contain 350 mg of C papaya leave exract and 150 mg of Tinospora cordifolia extract It is a FSSAI approved herb

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria for CIT groups 1. Male or female aged between 18-65 years. 2. Subjects willing to sign an informed consent with date prior to participation in the trial. 3. Patients with confirmed solid tumor and received at least one cycle of chemotherapy prior to screening visit. 4. Patients with a platelet counts between > 40000 and Inclusion criteria For Prophylaxis group: 1. Male or female aged between 18-65 years. 2. Subjects willing to sign an informed consent with date prior to participation in the trial. 3. Patients with confirmed solid tumor and received at least one cycle of chemotherapy prior to screening visit and with history of CIT during any previous cycle of chemotherapy

Exclusion criteria

Exclusion criteria: Exclusion Criteria for CIT groups 1. Pregnant or lactating women. 2. Subjects planning to receive any type of surgery. 3. Patients with platelet count less than 30000/ml. 4. Patients with thrombocytopenia presenting with active bleeding. 5. Patients who have received blood or blood product transfusion during the current illness or during past one week. 6. Patients with thrombocytopenia purpura (ITP) leukemia, hemophilia or bleeding diathesis. 7. Participation in another trial with another investigational product Exclusion criteria For Prophylaxis group: 1.Planning to receive any type of surgery. 2. Pregnant or lactating women. 3. Patients with thrombocytopenia presenting with active bleeding. 4. Patients who have received blood or blood product transfusion during the current illness or during past one week. 5. Patients with thrombocytopenia purpura (ITP) leukemia, hemophilia or bleeding diathesis. 6. Participation in another trial with another investigational product

Design outcomes

Primary

Measure	Time frame
Improvement in platelet count after chemotherapy % reduction in number of CIT cases as compared to previous cycleTimepoint: days 0, 7, 10 and 14	—

Secondary

Measure	Time frame
Hb%, TLC, DLC, Bilirubin, SGOT SGPT, ALP, Urea, Creatinine Timepoint: Days 0, 7, & 14	—

Countries

India

Contacts

Public ContactDebasish Hota

AIIMS

pharm_debasish@aiimsbhubaneswar.edu.in06742476011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026